SYNCORE BIOTECHNOLOGY CO., LTD.
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.syncorebio.com
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
- Conditions
- Metastatic Pancreas CancerPancreatic AdenocarcinomaLocally Advanced Pancreatic Cancer
- Interventions
- Drug: GemcitabineDrug: EndoTAG-1
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT03126435
- Locations
- 🇫🇷
Institut de Cancérologie de Lorraine, Nancy, France
🇫🇷Hôpital Privé Jean Mermoz, Lyon, France
🇭🇺Bács-Kiskun Megyei Kórház Onkoradiológiai Központ, Kecskemét, Hungary
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: SCB01A
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03020823
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Suang Ho Hospital, Taipei, Taiwan
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT03002103
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
🇨🇳Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳Mackay Memorial Hospital, Taipei, Taiwan
Study of SCB01A in Patient With Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: SCB01A
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT02488629
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy
- Conditions
- Solid Tumors
- Interventions
- Drug: SCB01A
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01159522
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
- Conditions
- Malignant Solid Tumour
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- SynCore Biotechnology Co., Ltd.
- Registration Number
- NCT01151930